ReviewTrends in molecular medicine2021
Mining Helminths for Novel Therapeutics.
Review in Trends in molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Use of helminth therapy for management of ulcerative colitis and Crohn's disease: a systematic review.Parasitology · 2022Pooled it
- Article
- Host insulin hijacking by a nematode receptor mediates developmental plasticity and sex ratio shifts.Nature communications · 2026Article
- Structural and functional analysis of the TGF-β mimic, TGM-2: an immunomodulatory helminth protein.Genes and immunity · 2026Article
- Excretory/secretory products from Hymenolepis nana adult worms alleviate ulcerative colitis in mice via tuft/IL-13 signaling pathway.Parasites & vectors · 2025Article
- Vaccination against helminth IL-33 modulators permits immune-mediated parasite ejection.Cell reports · 2025Article
- Protective effects ofFrontiers in immunology · 2025Article
- The Impact of Cell-Intrinsic STAT6 Protein on Donor T Cell-Mediated Graft-Versus-Tumor Effect.International journal of molecular sciences · 2024Article
- Animal healer for refractory diseases: Myth or reality?Heliyon · 2024Review
- IL-33-binding HpARI family homologues with divergent effects in suppressing or enhancing type 2 immune responses.Infection and immunity · 2024Article
- CD44 acts as a coreceptor for cell-specific enhancement of signaling and regulatory T cell induction by TGM1, a parasite TGF-β mimic.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Article
- Inhibition Effects ofPathogens (Basel, Switzerland) · 2022Article
- Immunization withTropical medicine and infectious disease · 2022Article
- A Good Day for Helminths: how parasite-derived GDH suppresses inflammatory responses.EMBO reports · 2022Article
- Long non-coding RNAs as possible therapeutic targets in protozoa, and in Schistosoma and other helminths.Parasitology research · 2022Review
- SJMHE1 protects against excessive iodine-induced pyroptosis in human thyroid follicular epithelial cells through a toll-like receptor 2-dependent pathway.International journal of medical sciences · 2022Article
- Excretory/secretory proteins inhibit host immune responses by downregulating the TLR4/NF-κB/MAPKs signaling pathway: A possible mechanism of immune evasion in parasitic nematodeFrontiers in immunology · 2022Article
- Helminth derived factors inhibit neutrophil extracellular trap formation and inflammation in bacterial peritonitis.Scientific reports · 2021Article
- Mining Anti-Inflammation Molecules FromFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Helminths are an emerging source of therapeutics for dysregulated inflammatory diseases. Excretory/secretory (ES) molecules, released during infection, are responsible for many of these immunomodulatory effects and are likely to have evolved as a means for parasite survival in the host. While the mechanisms of action of these molecules have not been fully defined, evidence demonstrates that they target various pathways in the immune response, ranging from initiation to effector cell modulation. These molecules are applied in controlling specific effector mechanisms of type 1 and type 2 immune responses. Recently, studies have further focused on their therapeutic potential in specific disease models. Here we review recent findings on ES molecule modulation of immune functions, specifically highlighting their clinical implications for future use in inflammatory disease therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.